1. Home
  2. CTKB vs PROK Comparison

CTKB vs PROK Comparison

Compare CTKB & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • PROK
  • Stock Information
  • Founded
  • CTKB 1990
  • PROK 2015
  • Country
  • CTKB United States
  • PROK United States
  • Employees
  • CTKB N/A
  • PROK N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CTKB Health Care
  • PROK Health Care
  • Exchange
  • CTKB Nasdaq
  • PROK Nasdaq
  • Market Cap
  • CTKB 430.6M
  • PROK 384.2M
  • IPO Year
  • CTKB 2021
  • PROK N/A
  • Fundamental
  • Price
  • CTKB $4.01
  • PROK $2.36
  • Analyst Decision
  • CTKB Hold
  • PROK Buy
  • Analyst Count
  • CTKB 4
  • PROK 5
  • Target Price
  • CTKB $6.00
  • PROK $6.25
  • AVG Volume (30 Days)
  • CTKB 1.2M
  • PROK 3.1M
  • Earning Date
  • CTKB 08-06-2025
  • PROK 08-12-2025
  • Dividend Yield
  • CTKB N/A
  • PROK N/A
  • EPS Growth
  • CTKB N/A
  • PROK N/A
  • EPS
  • CTKB N/A
  • PROK N/A
  • Revenue
  • CTKB $196,035,000.00
  • PROK $527,000.00
  • Revenue This Year
  • CTKB $0.74
  • PROK $105.79
  • Revenue Next Year
  • CTKB $7.85
  • PROK N/A
  • P/E Ratio
  • CTKB N/A
  • PROK N/A
  • Revenue Growth
  • CTKB N/A
  • PROK N/A
  • 52 Week Low
  • CTKB $2.37
  • PROK $0.46
  • 52 Week High
  • CTKB $7.63
  • PROK $7.13
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 59.09
  • PROK 45.54
  • Support Level
  • CTKB $3.68
  • PROK $2.15
  • Resistance Level
  • CTKB $4.19
  • PROK $2.46
  • Average True Range (ATR)
  • CTKB 0.21
  • PROK 0.34
  • MACD
  • CTKB 0.02
  • PROK -0.13
  • Stochastic Oscillator
  • CTKB 76.16
  • PROK 15.00

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: